Company Overview of Gamida Cell Ltd.
Gamida Cell Ltd. develops stem cell population expansion technologies and stem cell therapy products for transplantation and regenerative medicine. The company offers its products for treating a range of conditions, including blood cancers, such as leukemia, lymphoma, and solid tumors; autoimmune diseases; and non-malignant hematological diseases, such as sickle cell disease and thalassemia, neutropenia, acute radiation syndrome, and metabolic diseases. Its products include StemEx, a stem cell therapy product that addresses an unmet clinical need for patients with hematological malignancies; NiCord, a graft of stem/progenitor cells for hematological, autoimmune, and metabolic diseases; CordB...
Nahum Hafzadi 5 Street
Founded in 1998
Key Executives for Gamida Cell Ltd.
Chief Executive Officer, President and Director
Co-Founder, Chief Scientific Officer and Vice President of Research & Development
Head of the Stem Cell Consortium Projects
Vice President of US Operations
Compensation as of Fiscal Year 2016.
Gamida Cell Ltd. Key Developments
Gamida Cell Ltd Receives Fda Breakthrough Therapy Designation for Nicord
Oct 10 16
Elbit Imaging Ltd. announced that it was informed by Gamida Cell Ltd. that U.S. Food and Drug Administration has granted Breakthrough Therapy Designation status to Gamida's NiCord("Nicord"), due to improvement in absorption of neutrophils blood cells in bone marrow transplant for patients with high risk hematological malignancies (blood cancers). Breakthrough therapy designation is granted to a drug that is intended to treat serious or life-threatening diseases, and that preliminary clinical evidence indicates that the drug may demonstrate substantial improvement on a clinically significant endpoint(s) over available therapies. A breakthrough therapy designation entitles the company to various benefits, such as: intensive FDA guidance, involvement of senior FDA managers in the process, option for a FDA rolling review of Nicord marketing approval application in the U.S (i.e. the FDA may agree to review parts of the application file which are submitted in phases, with no obligation of filling the whole file prior to the review commencement). Gamida is engaged in developing cellular and immune therapies for the treatment of cancer and orphan genetic diseases. Gamida's products are examined via clinical trials for treatment of patients with hematological malignancies (blood cancers) such as leukemia and lymphoma and genetic hematological diseases such as sickle cell disease and thalassemia. At this stage, Gamida is unable to estimate the implications of the Breakthrough Therapy Designation regarding the future development of Nicord. The development of Nicord is not completed and there is no certainty that Nicord will be marketed on a commercial basis. The company holds approximately 89.9% of the share capital of Elbit Medical Technologies Ltd. (TASE:EMTC-M) (86.2% on a fully diluted basis) which, in turn, holds approximately 25% of the share capital in Gamida (22.5% on a fully diluted basis).
Gamida Cell Announces Appointment of Julian Adams and Kenneth I. Moch to its Board of Directors
Sep 15 16
Gamida Cell announced the appointment of Julian Adams, Ph.D., and Kenneth I. Moch to its Board of Directors. Dr. Adams has more than 30 years of experience in drug discovery and development with a strong focus on cancer. He currently serves as president of research and development at Infinity Pharmaceuticals. Mr. Moch has more than 30 years of experience in building private and public life science companies. He currently serves as a Managing Partner of The Salutramed Group. Mr. Moch currently sits on the Boards of Zynerba Inc. and M2Gen and served for over a decade on the Board of the Biotechnology Innovation Association (BIO).
Gamida Cell Announces First Patient with Sickle Cell Disease Transplanted in Phase 1/2 Study of CordIn™ as the Sole Graft Source
Jul 27 16
Gamida Cell announced that the first patient with sickle cell disease (SCD) has been transplanted with CordIn™. The transplant took place at UCSF Benioff Children's Hospital Oakland. CordIn is an experimental curative treatment for rare non-malignant diseases where bone marrow transplantation is the only currently available cure. These include hemoglobinopathies such as SCD and thalassemia, bone marrow failure syndromes such as aplastic anemia, genetic metabolic diseases and refractory autoimmune diseases. This unmet medical need represents a multi billion dollar market potential. Eight patients with SCD were transplanted in the first Phase 1/2 study performed in a double graft configuration. This study is still ongoing. Preliminary data from the first study will be summarized and published later this year. A Phase 1/2 of CordIn for the treatment of patients with aplastic anemia will commence later this year.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|